tirzepatide off fda shortage list confirms is still over, gives compounders a grace period Tirzepatide OFF FDA shortage list.

Visceral fat drives inflammation, promotes insulin resistance, contributes to fatty liver disease, and increases cardiovascular risk

Tirzepatide, with its shorter five-day half-life, shows wider fluctuations

Once weekly tirzepatide and treatment exposure of up to 104 weeks (median follow-up of 55 weeks) resulted in an HR of 0.81 (97.85% CI, 0.521.26) for the pooled tirzepatide group compared to the pooled comparator group from 116 composite MACE-4 endpoints (pooled tirzepatide: 60 (1.37 per 100 person-years) and pooled comparator: 56 (1.60 per 100 person-years)) and, therefore, met the criteria that treatment with tirzepatide was not associated with excess cardiovascular risk and initiated early close-out of SURPASS-4

NAD+ peptides: Cellular energy restoration NAD+ is nicotinamide adenine dinucleotide

OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation